A Single-center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment - A Phase IIa Study
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Oshadi D (Primary) ; Oshadi R (Primary)
- Indications Mesothelioma
- Focus Adverse reactions
- Sponsors Oshadi Drug Administration
- 16 Apr 2018 Status changed from not yet recruiting to suspended.
- 28 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018, according to ClinicalTrials.gov record.
- 28 Mar 2016 Planned initiation date changed from 1 Jul 2014 to 1 Dec 2016, according to ClinicalTrials.gov record.